PROMETHEUS Anser VDZ ANSERVDZ

Synonyms	Vedolizumab ENTYVIO Ab
Allscripts (AEHR) Order Name	Prometheus Anser VDZ
Sunrise Clinical Manager (SCM) Order Name	PROMETHEUS Anser Vedolizumab
EPIC Order Name	PROMETHEUS Anser VDZ
Clinical Info	Serum concentrations of vedolizumab (VDZ) may vary among equally dosed patients which can ultimately affect patient outcomes. Some patients may develop immunogenicity to VDZ by producing antibodies to vedolizumab (ATV) and the presence of persistent anti-vedolizumab antibody has been observed to substantially reduce serum concentrations of vedolizumab. The quantitative measurement of VDZ and ATV levels in serum provides healthcare providers with valuable information to help them gain a better understanding of the factors that may be affecting a patient’s loss of response. The PROMETHEUS Anser VDZ test is a next generation and more sensitive quantitative monitoring assay that allows healthcare providers to measure and monitor serum VDZ and ATV levels at any time during therapy. Incorporating therapeutic drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.
Specimen Type
Container	Gold Top Tube
Collection Instructions	Container/Tube: Gold top tube Specimen: 2 mL serum (0.5 ml min) Transport Temperature: Room Temperature (stable 7 days) or Refrigerated(stable 9 days)
Transport Instructions	Room Temperature (stable 7 days) or Refrigerated(stable 9 days)
Specimen Stability
Methodology	Electrochemiluminescence Immunoassay (ECLIA) Test Includes: Serum vedolizumab concentration (VDZ) and Antibodies to vedolizumab (ATV)
Days Performed	Monday - Friday TAT = 4 days
Performing Laboratory	Prometheus Therapeutics & Diagnostics
CPT	80280 Ab- If required 82542
PDM	1759072
Result Interpretation Assay Lower Limit of Quantification Serum vedolizumab concentration (VDZ) < 1.6 ug/mL Antibodies to vedolizumab (ATV) < 1.6 U/mL
Forms